By: ICN Bureau
Last updated : October 18, 2026 9:16 am
The company experienced a much stronger top-line growth
Specialty chemicals manufacturer Rossari Biotech Limited announced a stable financial performance for the second quarter of FY27 ended September 30, 2026. Correcting a common scale misinterpretation from lakhs to crores, the company’s consolidated net profit actually climbed to ₹38.91 crore (₹389.07 million), marking a 5.51% year-on-year increase from the ₹36.88 crore recorded in the same period last fiscal year.
The company experienced a much stronger top-line growth, with consolidated revenue from operations rising 19.01% YoY to Rs. 697.56 crore. On a sequential basis, revenues remained relatively flat compared to Q1 FY27, though net profit enjoyed a healthy 10.86% quarter-on-quarter expansion.
Operating profit (EBITDA) outpaced revenue growth, jumping 20.93% YoY to Rs. 86.97 crore. However, a substantial 65.06% surge in depreciation and amortization expenses (reaching Rs. 30.10 crore) tempered the flow-through to the final bottom line.
Alongside these financial updates, Rossari's board approved a strategic greenfield manufacturing facility lease in Saudi Arabia, positioning the business for broader international footprint expansion in the coming quarters